VERV
Income statement / Annual
Last year (2023), Verve Therapeutics, Inc.'s total revenue was $11.76 M,
an increase of 505.77% from the previous year.
In 2023, Verve Therapeutics, Inc.'s net income was -$200.07 M.
See Verve Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$11.76 M
|
$1.94 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$184.95 M |
$6.71 M |
$3.38 M |
$1.33 M |
$106,000.00 |
| Gross Profit |
-$173.19 M |
-$4.77 M |
-$3.38 M |
-$1.33 M |
-$106,000.00 |
| Gross Profit Ratio |
-14.73 |
-2.46 |
0 |
0 |
0 |
| Research and Development
Expenses |
$184.95 M
|
$130.10 M
|
$68.20 M
|
$35.37 M
|
$11.14 M
|
| General & Administrative
Expenses |
$49.94 M
|
$37.53 M
|
$18.87 M
|
$5.26 M
|
$2.50 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$49.94 M
|
$37.53 M
|
$18.87 M
|
$5.26 M
|
$2.50 M
|
| Other Expenses |
$0.00 |
$1.49 M |
-$33.39 M |
-$5.24 M |
-$5.93 M |
| Operating Expenses |
$234.88 M |
$167.63 M |
$87.07 M |
$40.63 M |
$13.64 M |
| Cost And Expenses |
$234.88 M |
$167.63 M |
$87.07 M |
$40.63 M |
$13.64 M |
| Interest Income |
$0.00 |
$6.87 M |
$142,000.00 |
$162,000.00 |
$278,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$5.46 M
|
$6.71 M
|
$3.38 M
|
$1.33 M
|
$106,000.00
|
| EBITDA |
-$217.67 M
|
-$162.88 M
|
-$85.53 M
|
-$39.30 M
|
-$13.54 M
|
| EBITDA Ratio |
-18.51 |
-83.92 |
0 |
0 |
0 |
| Operating Income Ratio
|
-18.98
|
-85.36
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$23.33 M
|
$8.35 M
|
-$33.25 M
|
-$5.08 M
|
-$5.66 M
|
| Income Before Tax |
-$199.79 M |
-$157.33 M |
-$120.31 M |
-$45.70 M |
-$19.30 M |
| Income Before Tax Ratio
|
-16.99
|
-81.06
|
0
|
0
|
0
|
| Income Tax Expense |
$275,000.00 |
$53,000.00 |
-$1.68 M |
-$162,000.00 |
-$278,000.00 |
| Net Income |
-$200.07 M |
-$157.39 M |
-$118.64 M |
-$45.54 M |
-$19.02 M |
| Net Income Ratio |
-17.02 |
-81.09 |
0 |
0 |
0 |
| EPS |
-3.12 |
-2.91 |
-2.45 |
-0.94 |
-0.39 |
| EPS Diluted |
-3.12 |
-2.91 |
-2.45 |
-0.94 |
-0.39 |
| Weighted Average Shares
Out |
$64.18 M
|
$54.02 M
|
$48.51 M
|
$48.22 M
|
$48.22 M
|
| Weighted Average Shares
Out Diluted |
$64.18 M
|
$54.02 M
|
$48.51 M
|
$48.22 M
|
$48.22 M
|
| Link |
|
|
|
|
|
